I. Introduction
===============

Autoinflammatory disorders are known as the hyperactivation of the innate immune system without high-titter auto-antibodies and autoreactive lymphocytes. Majeed syndrome, deficiency of interleukin-1 receptor antagonist (DIRA), and pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA) syndrome, were the representative autoinflammatory diseases with non-infectious osteomyelitis. Chronic non-bacterial osteomyelitis (CNO) is a kind of an autoinflammatory bone disorder (ABD) and a rare non-infectious inflammatory bone disease of unknown etiology that mostly affects children and adolescents[@B1][@B2]. Chronic recurrent multifocal osteomyelitis (CRMO) is another diagnostic name for CNO because of its auto-inflammatory, non-infectious disorder of the bone with recurrent episodes of pain and fever resembling bacterial osteomyelitis with sterile lesion cultures that are unresponsive to antibiotic or anti-inflammatory medications. CNO/CRMO was first reported in 1972 by Giedion et al.[@B3] as subacute and chronic 'symmetrical' osteomyelitis. CRMO mainly occurred in the children with a female predominance, with the average age of 10 years between the ages of 4 to 14 years. The affected sites are the metaphysis of long bones, pelvis, clavicle, and mandible[@B1][@B2][@B3][@B4][@B5].

CNO can appear at any site in the skeleton exhibiting radiographic similarities to bacterial osteomyelitis with osteolytic and sclerotic lesions. Due to the sterile inflammation of the involved bone and atypical clinical features, the culture of the affected sites shows no bacterial infections. Only a biopsy should be considered for the final diagnosis of CNO to exclude both infected osteomyelitis and malignant bone disease. ([Table 1](#T1){ref-type="table"}) This review article will reveal the basic nature of CNO/CRMO with a specific focus on the jaw for a better understanding and ideal management of ABD by maxillofacial surgeons.

II. Clinical Presentation of CNO/CRMO in the Jaw
================================================

The clinical presentation of CNO/CRMO in the jaw is very diverse with the main symptom of recurrent jaw pain and swelling with or without a general fever. Localized skin redness caused by paraosseous inflammation is a rare symptom. Inflammatory laboratory markers including erythrocyte sedimentation rate (ESR), absolute neutrophil count and white blood cell count (WBC), could be increased. These first findings in an outclinic setting could allow clinicians to suspect any kind of bacterial osteomyelitis in the jaw. CRMO in the jaw commonly has symmetrical and multifocal bony lesions in the long bones exhibiting a lytic lesion or progression to sclerosis or hyperostosis radiographically[@B6][@B7]. Unlike other inflammatory osteomyelitis, CRMO has no infectious sources such as retained roots, periodontitis, or pathology in the oral cavity. No previous bisphosphonate therapy or radiation therapy could exclude bisphosphonate related osteonecrosis of jaw (BRONJ) or osteoradionecrosis. A bone biopsy is required to confirm the final diagnosis and to exclude any infected bacterial osteomyelitis or other malignancies. Even though the histopathological features are non-specific for CRMO, most of the bone biopsy could show slight inflammation with lymphocyte infiltration with fibrosis and lack of organisms.

In adult CRMO cases, most of the patients could be usually diagnosed with complex symptoms of synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO), which is currently common with additional symptoms in the Western region. Autoinflammatory organ involvement in CRMO is seen in 8% of cases with psoriasis and palmoplantar pustulosis, 10% with inflammatory bowel disease (IBD), 10% with severe acne, and 25% with ankylosing spondylitis[@B8][@B9].([Fig. 1](#F1){ref-type="fig"})

1. Epidemiology and diagnosis
-----------------------------

Epidemiological data in CNO/CRMO is scarce and even more rare with jaw involvement data compared to other bony involvements from simple case reports, case series, and regional cohort studies. Although there have been no global epidemiologic studies until now, the greatest incidence of sporadic CNO has been found in European countries. Genetic predispositions could be suggested in the pathophysiology of sporadic CNO from familial clusters of CNO/CRMO and high incidences of comorbid-affiliated inflammatory conditions including psoriasis and IBD in CNO patients and first-degree family members by approximately 50%[@B10][@B11].

CNO is occurred in all ages with 7 to 12 years peak onset, female predominant. The clinical presentation of CNO is not typical having a relative self-limiting monofocal bone lesions or the most severe form of CRMO. Clinical signs of CNO/CRMO include bone pains having arthritis, local swelling with heat and redness. And associated skin manifestations could involve palmoplantar pustulosis, psoriasis, and acne. Elevated temperatures or pathological fractures of affected vertebra could be occurred in severe cases[@B10][@B12].

Asymptomatic bone lesions occur on the metaphysis of long bones, clavicle, humerus, vertebral column, pelvic region, femur, tibia, ankle, and calcaneus. Due to these clinical signs, CNO/CRMO could sometimes be mistaken as infectious osteomyelitis secondary to a rather mild type. Routine laboratory findings with inflammatory parameters such as WBC, C-reactive protein (CRP), and ESR, are usually normal or mildly elevated.

Radiographic imaging is essential for CNO/CRMO diagnosis with excluding differential diagnoses. Inflammatory bony lesions as radiolucent or sclerotic lesions in plain radiographs could be identified, and computed tomography or magnetic resonance imaging (MRI) are helpful tools particularly in early stage of CNO/CRMO[@B13][@B14], and especially in CRMO in jaw.([Fig. 2](#F2){ref-type="fig"}) MRIs could detect initial bony inflammation with surrounding soft tissue edema in the T2-weighted sequences and gadolinium-enhanced T1 sequences with fat saturation. Whole body MRI imaging could be done for checking any silent lesions, especially in the vertebral column, and for monitoring of disease occurrences such as linear fractures or surrounding soft tissue damage during the follow-up period[@B15][@B16].

Bone biopsies for the definite and differential diagnosis of CNO/CRMO should be performed, and any suspicious disease under 2 years of age should be followed by a prompt bony biopsy, due to its rarity[@B17][@B18]. Bony malignancies including lymphoma, leukemia, and primary and secondary bone tumors, could be diagnosed with other infectious diseases and immune diseases such as immunodeficiency in interleukin (IL)-12, Langerhans cell histiocytosis (LCH), and other autoinflammatory disorders and should be diagnosed differentially[@B17][@B18]. Cellular atypism from innate immune cells to leukocytes and plasma cells could suggest a disease course between innate and adaptive immune mechanisms[@B19][@B20].

2. Sporadic CNO/CRMO
--------------------

Sporadic CNO/CRMO has been known to have a broad clinical symptoms from mild monofocal bone inflammation to severe recurrent multifocal inflammation, such as vertebral compression fracture, arthritis, skin, or intestinal inflammatory disorder. This sporadic CNO/CRMO could be presented as clinically related phenotypes regardless of envirionmental factors. Most of sporadic type occurred in childhood or preadolescent ages between 7 to 12 years of age, additional bony inflammation could also be occurred later, but this is not severe compared with monogenic CNO/CRMO[@B2][@B21].

The pathophysiological understanding of sporadic CNO/CRMO is less known as the imbalance between proinflammtory and antiinflammatory cytokines, of which the mechanisms are known to govern the cell and receptor-specific induction of cytokines and chemokines[@B22][@B23]. Monocytes from CRMO patients fail to express the immune regulatory IL-10 in response to Toll-like receptor (TLR) 4 stimulation with lipopolysaccharide. Impaired IL-10 expression is partially caused by the reduced activation of mitogen-activated protein kinases (MAPK) and extracellular signal regulated kinase (ERK) 1, resulting in impaired activation and nuclear shuttling of the transcription factor signaling protein (SP) 1 and subsequent altered recruitment of Sp-1 to the IL-10 promoter[@B24][@B25].

3. Familial or monogenic CNO/CRMO
---------------------------------

Familial or monogenic CNO/CRMO is not known its molecular pathophysiology, but single gene mutations involving CNO/CRMO are known to three main diseases such as Majeed syndrome by LPIN2 mutations, DIRA by IL1RN mutations, and PAPA by proline-serine-threonine phosphatase-interacting protein 1 (PSTPIP1) mutations. These monogenic disorders are associated with multiprotein complexes, inflammasomes which mediate the cleavage and subsequent release of proinflammatory cytokines IL-1β and IL-18[@B17][@B22][@B26][@B27][@B28][@B29].

Majeed syndrome is an autosomal recessive disorder that is characterized with early-onset CRMO, Sweet syndrome-like skin rash, dyserythropoietic anemia, and joint contractures. It is caused by the loss of function mutations in the *LPIN2* gene which encodes phosphatase lpin2, a phosphatidate phosphatase that plays a role in lipid metabolism, thus resulting in the overactivation of TLR4 pathways and systemic inflammation. Lipin2-deficient monocytes produce high amounts of pro-inflammatory cytokines IL-6 and tumor necrosis factor alpha (TNF-α) when stimulated by saturated fatty acids. The overexpression of *LPIN2* on the other hand reduces inflammatory cytokine levels[@B22]. For Majeed syndrome, there is evidence that it is an IL-1β-mediated disease, since bone inflammation and serum inflammation markers improve in response to an IL-1β blockade, while TNF-α blockers have almost no effect[@B26]. Therefore, nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and IL-1-blocking agents should be considered as empirical treatment.

DIRA is an autosomal recessive mutation in the *IL1RN* gene, encoding for the IL-1 receptor antagonist (IL-1RA), a post-translational regulator of IL-1 signaling resulting in uncontrolled proinflammatory cytokine and chemokine expression. DIRA is characterized by early-onset oral mucosal ulceration, pustular rash, rib widening with periostitis, multifocal osteolytic lesions, and heterotopic ossification. DIRA leads to a severe systemic inflammatory response syndrome and respiratory failure[@B17] due to the lack of functional IL-1RAs and subsequently uncontrolled IL-1β signaling. Recombinant IL-1RAs therapy is known for therapeutic option[@B17][@B27].

PAPA is an autosomal dominant mutation in the *PSTPIP1* gene which binds to pyrin and regulates the actin cytoskeleton. Pyrin is a central negative regulator of the NLRP3 inflammasome by releasing of IL-1β. PAPA is characterized by pyoderma gangrenosum-like ulcerative lesions, cystic acne and sterile erosive arthritis. Therapeutic options involve local and/or systemic steroids, thalidomide, cyclosporine, tacrolimus, intravenous immunoglobulin, TNF-α blockers, and IL-1 blocking agents[@B28][@B29].

III. CNO/CRMO Studies
=====================

CNO in the jaw presents with mild or non-specific clinical symptoms, which is not recognized by patients and medical staff resulting in a delayed final diagnosis. Although CNO is associated with other general syndromes or genetic diseases including SAPHO, Majeed syndrome, DIRA, and PAPA, a genetic or molecular basis for animal studies have been provoked and found to be associated with other autoinflammatory conditions such as IBD, acne, ankylosing spondylitis, and psoriasis.

1. Microbiome in CNO/CRMO
-------------------------

A microbiota, microbiome, is the collective genomes of commensal or pathogenic microorganisms in plants or animals. Disturbances to the microbiome, particularly of the gut, have been proven to contribute to altered immune cell distribution and inflammatory phenotypes in several diseases including immunologic, hormonal, and metabolic disorders[@B30]. In rheumatoid arthritis, the replacement of *Lactobacillus* spp. with *Prevotella* spp. has been linked to disease activity and outcomes. Liao et al.[@B31] published the first study that found that disturbances in the gut microbiome may contribute to sterile bone inflammation.

In humans, it could be proposed a potential pathophysiological connection of an altered skin microbiome and aseptic bone inflammation in CNO, because both of severe cystic acne and CNO, share the imbalanced expression and secretion of proinflammatory antiinflammatory cytokines[@B32][@B33][@B34].

2. Murine models of CRMO
------------------------

Two well-characterized murine models have been developed, chronic multifocal osteomyelitis (cmo) mice carrying a spontaneous homozygous mutation (p.L98P) and lupo mice carrying a chemically-induced homozygous mutation (p.I282N) in the *Pstpip2* gene[@B35][@B36]. Two models could be developed to cytokine and chemokine dysregulation, systemic inflammation, extramedullary hematopoiesis, skin inflammation, and sterile osteomyelitis. As in the case of CRMO patients, cmo mice exhibit a central involvement of IL-1β in disease pathophysiology and the complete deficiency of *Pstpip2* gene results in the dysregulated production of IL-1β by neutrophils and enhanced osteoclastogenesis[@B35].

3. Chemokine and cytokine dysregulation in CNO/CRMO
---------------------------------------------------

The molecular mechanisms of CNO/CRMO have been suggested as many different pathways and hypotheses, inflammasome and consequent imbalance between proinflammatory and anti-inflammatory cytokines.

TLR4/MAPK/inflammasome signaling pathway could contribute to the inflammatory phenotype in CRMO, inflammatory bone loss and synovial inflammation in IL-10-deficient mice were linked to increased NOD-like receptor protein 3 (NLRP3) inflammasome activation[@B37][@B38]. This activation will increase mRNA expression of inflammasome including ASC, NLRP3, and caspase-1, as well as increased IL-1β transcription and release from monocytes of CRMO patients[@B37][@B38]. An immunomodulatory reversible function by IL-10 and IL-19 on enhanced inflammasome activation with IL-1β secretion could be suggested[@B23].

The imbalanced expression of antiinflammtory cytokines such as IL-10 and IL-19, and pro-inflammatory cytokines such as IL-1, IL-6, TNF-α, and IL-20, may result in increased osteoclast differentiation and activation through enhanced interactions between the receptor activator of nuclear factor-κB (RANK) and its soluble ligand RANKL on osteoclast precursor cells[@B19][@B33]. IL-10 expression is predetermined by genetic variants within the IL-10 proximal promoter region, by blocking encoding for high IL-10 expression (GCC)[@B27], which is one of clue for the IL-10 medication to the CRMO patients.

Additionally, a CRMO susceptibility gene has been identified through whole exome sequencing and gene expression microarrays. *FBLIM1* has been suggested to act as an antiinflammatory molecule that controls bone remodeling through the regulation of RANKL activation through ERK1/2 phosphorylation. On the transcriptional level, *FBLIM1* expression is regulated by the transcription factor STAT3. Since the immune regulatory cytokine IL-10 induces STAT3 activation, the aforementioned haplotype blocks within the IL-10 promoter may be involved in the pathophysiology of CNO. Cox et al.[@B39] demonstrated that IL-10 promoter haplotypes may contribute to reduced STAT3 activation. Although preliminary results regarding the kinetics of innate and adaptive inflammatory responses in CNO/CRMO, outline for future targeted medications should be continued based on the specific expressions of cytokines and chemokines[@B19][@B40].

IV. Treatment and Biomarkers for CNO/CRMO in the Jaw
====================================================

The treatment of patients with CNO/CRMO in the jaw should not always be through surgical means and that medications should be considered. Only small portions of bone biopsies including both cortical and marrow bony architecture could be confirmed for the exclusion of any bacterial osteomyelitis. NSAIDs are representative medication drugs for CNO/CRMO. Other recently approved medications include corticosteroids, bisphosphonates and disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate, sulfasalazine and anti-TNF agents.([Fig. 3](#F3){ref-type="fig"})

1. Biomarkers for CNO diagnosis and monitoring
----------------------------------------------

Sstandardized and accepted parameters have not yet to be reported despite many basic studies and follow-up clinical studies regarding CNO/CRMO biomarkers. Known classical inflammation markers, such as CRP and ESR, are not specific. Therefore, in unclear cases, bone biopsies must be considered as the first action prior to prescribing any medications[@B32].

A clinical score for CNO patients was developed by Jansson et al.[@B41], and Beck et al.[@B42] presented the Pediatric CNO (PedCNO) score, which includes 5 measurements such as ESR, number of radiological lesions, severity of disease estimated by the physician, severity of disease estimated by the patient or parent, and the Childhood Health Assessment Questionnaire. However, the clinical score has not been considered for other ABD involving the jaw, metabolic disorders, lymphoma, leukemia, LCH, and mycobacterial bone infections. El-Shanti and Ferguson[@B11] identified a set of nine serum inflammation markers including IL-6, IL-12, MIG, RANTES, IL-1RA, soluble IL-2 receptor (sIL-2R), monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1b (MIP-1b) and mast cell derived chemokine eotaxin. These serum protein arrays may be used for the diagnosis of CNO/CRMO, but larger multi-institute cohort studies should be performed.

Unbalanced cytokine and chemokine expression could be used for the diagnosis of CNO/CRMO[@B19][@B38][@B43]. Molecular works of monocytes from CRMO patients showed decreased levels of IL-10, IL-1RA and granulocyte monocyte colony-stimulating factor, and showed increased levels of IL-1β, IL-6, TNF-α, IL-8, Interferon gamma-induced protein 10, MCP-1, MIG, MIP-1a, and MIP-1b[@B38][@B43]. And the increased levels of the NLRP3 from inflammatory infiltrates of CNO/CRMO could be translated into IL-1β and IL-10 protein expression in bacterial osteomyelitis. This NLRP3 component in the gene expression profiles would be applicated in the CNO/CRMO in jaw cases.

Not like in the bacterial osteomyelitis, predominant neutrophils and monocytes are usually moderately infiltrated with bone marrow fibrosis in the CNO/CRMO bone biopsy[@B32][@B33].

2. Treatments of CNO in the jaw
-------------------------------

Any pathological involvement of the jaw should be managed with medicinal approaches at first and not with surgical considerations. Usually, NSAIDs, corticosteroids, and DMARDs such as methotrexate or sulfasalazine, could be considered for general CNO/CRMO management. Anti-TNF agents including proinflammatory cytokines and bisphosphonates (BPs) could be additionally considered.([Fig. 3](#F3){ref-type="fig"})

NSAIDs are the first-line treatment of choice for the treatment of initial CNO/CRMO in jaw patients with the most common choice being 10 to 15 mg/kg/day of naproxen in 2 divided doses which is effective in 70% of patients[@B9]. NSAIDs are effective in approximately two-thirds of CNO/CRMO patients, and NSAIDs are more effective in CNO patients compared with only CRMO patients[@B24]. And another data showed that NSAIDs did not induce true real remission in CNO patients with a clinically asymptomatic state in 43% after 6 months and in 51% at 12 months, and also NSAIDs may not be sufficient for long-term remission in the majority of patients[@B9][@B42].

For the management of CRMO in jaw patients, definitely NSAIDs should be considered as the first medication only excluding the relapsed or no completed remission cases. Cyclooxygenases inhibition is activated by NSAIDs for the conversion of arachidonic acid into prostaglandins, which is essential procedure of osteoclast activation in jaw[@B3]. Jaw edema or any kinds of structural damage with NSAIDs should be followed-up periodically.

Widely accepted treatment consensus remains empirical, despite many collected case series of NSAID medications, measurements of disease activity, treatment goal definitions, and outcome measurements. Corticosteroids in CNO/CRMO management could be recommended as an intermediately between failed NSAIDs and other drugs initiation. Oral glucocorticoid medication is recommended as 2 mg prednisone/kg/day for 1 week and tapered discontinuation by 25% every 5 days[@B44]. Intravenous steroid infusion could be effective in selected recurrent patients but a standardized medication protocol is not known yet[@B45]. The inhibition pathway of phospholipase A2 is well known for reduced prostaglandin levels as the corticosteroids mechanisms. In the case of CNO/CRMO patients, the inhibition of nuclear factor-κB-dependent gene activation could be also useful for the reduced proinflammatory cytokine levels such as IL-6 and the TNF-α gene[@B39].

In spite of its quick control of inflammatory activity, long-term effects had not been expected in CNO/CRMO patients. The effective management with bisphosphonate or anti-TNF agents have been reported to be highly effective for the long-lasting remission[@B12][@B33][@B42]. The representative osteoclast inhibition drug, BPs, could increase bone mass with improved mineralization in the postmenopausal and glucocorticoid-induced osteoporosis. Although BPs have severe side effects such as BRONJ, this is effective in CNO/CRMO patients by modify pains through suppression of proinflammatory cytokines, such as TNF-α, IL-6, and IL-1[@B46]. BPs could be recommended in no effective cases of NSAIDs, corticosteroids, or DMARDs. Among BPs, pamidronate could be first recommended in the refractory pediatric CNO/CRMO patients, which could be administered as an initial dose of 0.5 mg/kg/day followed by 1 mg on days 2 and 3 mg every 3 months, or 1 dose of 1 mg/kg every month for 1 to 6 months[@B32][@B47][@B48][@B49].

Due to its exact pathogenesis is not revealed, any molecules during having its role in a little bit known sequences could be blocked for the additional treatment option in CNO/CRMO patients. Methotrexate and sulfasalazine are known to reduce inflammatory cytokine expression in recalcitrant CNO/CRMO patients and are more commonly used in North America and Europe[@B1]. More recently, DMARDs may be used more and more due to several side effects or no complete remission of NSAIDs especially in CRMO in jaw[@B24].

Since IL-1 and TNF-α are generally important in the inflammatory pathogenesis, IL-1 blocking agents and TNF-α inhibitors can be also considered in CNO/CRMO treatment. TNF inhibitors could also be used with NSAIDs and corticosteroids for specifically blocking TNF-α and for restoring the balance between this highly potent proinflammatory cytokine and immune modulatory cytokines IL-10 and IL-19[@B23][@B24][@B25][@B27]. Although there is no reliable report, RANKL blockade with denosumab, which is the recombinant RANK ligand inhibitor, may reduce osteoclast activation and inflammatory bone loss in CRMO in jaw. These functions are deduced from the differentiation and activation of osteoclasts, TNF-α versus IL-10 and IL-19, which are counteracting mediators[@B50].

Recently, biomarkers including IL-12, MCP-1, and sIL-2R were introduced for acting of treatment response to NSAIDs[@B51][@B52]. Further evaluation of these medications, such as IL-12, MCP-1, and sIL-2R, could be used as the progression of CNO/CRMO in jaw.

V. Conclusion
=============

CRMO in jaw must be diagnosed with the differentiation of chronic bacterial osteomyelitis, and a bone biopsy is essential. The early diagnosis of CRMO in jaw will prevent unnecessary and prolonged antibiotic usage and unnecessary surgical intervention. The updated researches of several pathophysiological alterations in CNO/CRMO should be studied more for its exact causes and allow for the creation of target-directed treatment options.
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![Schematic drawing showing the autoinflammatory organ involvement of chronic recurrent multifocal osteomyelitis (CRMO)[@B8][@B9].](jkaoms-45-68-g001){#F1}

![Representative computed tomographic views of chronic recurrent multifocal osteomyelitis in jaw case showing the lesion in the right mandible, axial (A), coronal (B), and sagittal (C).](jkaoms-45-68-g002){#F2}

![Schematic diagrams for the generalized medication protocols of CNO/CRMO in the jaw. (CNO: chronic non-bacterial osteomyelitis, CRMO: chronic recurrent multifocal osteomyelitis, NSAIDs: nonsteroidal anti-inflammatory drugs, TNF-α: tumor necrosis factor alpha)](jkaoms-45-68-g003){#F3}

###### Comparisons between chronic recurrent multifocal osteomyelitis (CRMO) and infectious osteomyelitis in jaw
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                                             CRMO                Infectious osteomyelitis
  ------------------------------------------ ------------------- --------------------------
  Age of onset (yr)                          10                  \<5
  Affected bones                             Several             One
  Personal or familial history               Psoriasis or IBD    None
  Bacterial culture from the bone or blood   Negative            Positive
  Recurrence                                 Common              Rare
  Management                                 Medication          Surgery+medication
  Biomarkers                                 No revealed yet     Inflammatory markers
  Follow-up                                  Before adolescent   Until healing periods

(IBD: inflammatory bowel disease)
